To view this email as a web page, click here.

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

HEPATITIS C

TODAY'S HEADLINES

Hepatitis C pricing heats up with new drug

The FDA just approved Merck's hepatitis C drug, Zepatier. Does this signal higher or lower prices for hepatitis C medications? Read more

Top 5 things to know about Zika virus

The mosquito-borne epidemic that originated in Brazil has been declared a global health emergency. Here's what you need to know about the virus. Read more

CONTINUING PHARMACY EDUCATION

LAW: Primer on biosimilar agents

This month's CE activity is open for pharmacists and pharmacy technicians, "LAW: Primer on biosimilar agents." Pharmacists and pharmacy technicians can earn up to 2 hours of CPE law credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

First chemo drug to show survival benefit for liposarcoma passes

FDA recently approved the first chemotherapy drug to demonstrate survival benefit for liposarcoma that cannot be removed by surgery or is advanced. Details

February 10, 2016

Related Articles

Hepatitis C drugs come under fire again

FDA approves new indication for Hib vaccine

Click to contact the editorial team. Click to contact the sales team.

Part of the

ModernMedicine logo

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply.
Please use the links provided if you have questions or concerns regarding this email or your subscription.

This email was sent by: %%Member_Busname%%
%%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%

 

NEWSLETTER

Forward to a Friend
Privacy Statement
Terms of Service
Update Profile
Add/Remove Newsletters
Contact Us